- Home
- HTCO vs RGLS Comparison
HTCO vs RGLS Comparison
Compare HTCO & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTCO
- RGLS
- Stock Information
- Founded
- HTCO N/A
- RGLS 2007
- Country
- HTCO Singapore
- RGLS United States
- Employees
- HTCO N/A
- RGLS N/A
- Industry
- HTCO
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- HTCO
- RGLS Health Care
- Exchange
- HTCO NYSE
- RGLS Nasdaq
- Market Cap
- HTCO 92.5M
- RGLS 106.7M
- IPO Year
- HTCO N/A
- RGLS 2012
- Fundamental
- Price
- HTCO $1.17
- RGLS $1.48
- Analyst Decision
- HTCO
- RGLS Strong Buy
- Analyst Count
- HTCO 0
- RGLS 6
- Target Price
- HTCO N/A
- RGLS $10.33
- AVG Volume (30 Days)
- HTCO 159.1K
- RGLS 263.0K
- Earning Date
- HTCO 11-01-2024
- RGLS 11-07-2024
- Dividend Yield
- HTCO N/A
- RGLS N/A
- EPS Growth
- HTCO N/A
- RGLS N/A
- EPS
- HTCO N/A
- RGLS N/A
- Revenue
- HTCO $95,257,538.00
- RGLS N/A
- Revenue This Year
- HTCO N/A
- RGLS N/A
- Revenue Next Year
- HTCO N/A
- RGLS N/A
- P/E Ratio
- HTCO N/A
- RGLS N/A
- Revenue Growth
- HTCO N/A
- RGLS N/A
- 52 Week Low
- HTCO $0.21
- RGLS $1.08
- 52 Week High
- HTCO $1.63
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- HTCO N/A
- RGLS 44.54
- Support Level
- HTCO N/A
- RGLS $1.47
- Resistance Level
- HTCO N/A
- RGLS $1.65
- Average True Range (ATR)
- HTCO 0.00
- RGLS 0.11
- MACD
- HTCO 0.00
- RGLS -0.00
- Stochastic Oscillator
- HTCO 0.00
- RGLS 15.79
About HTCO CARAVELLE INTERNATIONAL GROUP
Caravelle International Group is an international operator of ocean transportation services. It is engaged in the seaborne transportation service under voyage contracts as well as vessel service for and on behalf of ship owners. The company has two operating segments namely, ocean transport and Heating business. The company derives the majority of its revenue from the Ocean transportation business. The company derives freight revenue from voyage contracts and provides vessel service.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.